The effect of dactinomycin on cellular respiration and accompanying ATP formation was investigated in Jurkat and HL-60 cells. Cellular mitochondrial oxygen consumption (measured by a homemade phosphorescence analyzer) and ATP content (measured by the luciferinluciferase bioluminescence system) were determined as functions of time t during continuous exposure to the drug. The rate of respiration, k, was the negative of the slope of [O 2 ] versus t. Oxygen consumption and ATP content were diminished by cyanide, confirming that both processes involved oxidations in the mitochondrial respiratory chain. In the presence of dactinomycin, k decreased gradually with t, the decrease being more pronounced at higher drug concentrations. Cellular ATP remained constant for 5 h in untreated cells, but in the presence of 20 µM dactinomycin it decreased gradually (to one-tenth the value at 5 h for untreated cells). The drug-induced inhibition of respiration and decrease in ATP were blocked by the pancaspase inhibitor benzyloxycarbonyl-Val-Ala-DL-Asp-fluoromethyl ketone (zVAD-fmk). A rapid but temporary decrease in cellular ATP observed on the addition of zVAD-fmk was shown to be due to DMSO (added with zVAD-fmk). The effect of dactinomycin on respiration differed from that of doxorubicin. Plots of [O 2 ] versus t were curved for dactinomycin so that k decreased gradually with t. The corresponding plots for doxorubicin were well fit by two straight lines; so k was constant for ∼150 min, at which time k decreased, remaining constant at a lower level thereafter. The results for cells treated with mixtures of the two drugs indicated that the drugs acted synergistically. These results show the onset and severity of mitochondrial dysfunction in cells undergoing apoptosis induced by dactinomycin.
Introduction
Dactinomycin is an important anticancer chromopeptide. 1 The drug is known to intercalate between DNA base pairs and inhibit transcription. 2 This toxic effect leads to cell death, primarily by apoptosis. The drug is also commonly used in vitro to execute apoptosis.
Apoptosis is initiated by activating cellular targets (e.g., the pro-apoptotic Bcl-2 family member Bid), which permeabilize the outer mitochondrial membrane, causing release of soluble proteins (e.g., cytochrome c and SMAC/Diablo) from the mitochondrial intermembrane space. In the presence of ATP (or dATP), released cytochrome c binds to Apaf-1 (apoptotic protease-activating factor 1), forming an oligomer (apoptosome) that activates cysteine proteases (caspases). 3 However, cytochrome c-and apoptosome-independent pathways for caspase activation are also known. 4 Apoptosis is executed by caspases, which lead to mitochondrial dysfunction. 5 The mitochondrial perturbation involves opening the permeability transition pores, which are formed at contact sites between the inner and outer mitochondrial membranes. When opened, these pores dissipate the mitochondrial membrane potential (∆ψ), permit further passage of low-molecular-weight apoptogenic proteins (e.g., cytochrome c), and generate reactive oxygen species. 6 The initial release of cytochrome c and dissipation of ∆ψ occur in the absence of caspase activities. 7 If caspases are blocked by zVAD-fmk, 8 then the mitochondrial ∆ψ can be regenerated despite cytochrome c leakage. 9 In the presence of active caspases, mitochondrial dysfunctions remain. The impact of the loss of cytochrome c and dissipation of ∆ψ on oxidative phosphorylation during apoptosis remains unclear.
We present here the results of measurements of cellular respiration and ATP content during continuous exposure to dactinomycin. The goal of these experiments was to describe the onset and severity of mitochondrial dysfunction in cells undergoing apoptosis in response to dactinomycin. The results show that cyanide-sensitive respiration and accompanying ATP formation are inhibited in cells treated with dactinomycin and that the inhibition is mediated by caspase activity. The effect of dactinomycin on respiration is compared with that of doxorubicin.
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Materials and Experimental Procedures
Chemicals. Dactinomycin (actinomycin D, M w 1255.43) was purchased from Merck (Whitehouse Station, NJ). The Pd(II) complex of meso-tetra-(4-sulfonatophenyl)-tetrabenzoporphyrin (Pd phosphor sodium salt) was purchased from Porphyrin Products (Logan, UT). Fetal bovine serum and RPMI-1640 medium 10-040 with L-glutamine (pH 7.15 ( 0.1) were purchased from Mediatech (Herndon, VA). Jurkat clone E6-1 human acute T-cell leukemia (TIB-152) and human leukemia-60 (HL-60) were purchased from American Tissue Culture Collection (Manassas, VA). The luciferin-luciferase mixture (0.2 mg luciferin and 22 000 units luciferase per vial, stored at -20°C) and ATP (2 micromol per vial, stored at -20°C) were purchased from Chrono-Log (Havertown, PA). Caspase inhibitor I (zVAD-fmk, M w 467.5) was purchased from Calbiochem (San Diego, CA). The remaining reagents were purchased from Sigma-Aldrich (St. Louis, MO).
Solutions. Dactinomycin solution was made fresh in dH 2 O; its final concentration was determined by absorbance at 440 nm using an extinction coefficient of 24 450 M -1 cm -1
. Aqueous solution of ATP (0.4 mM) was made fresh in 10 mM Tris-HEPES (pH 7.5); its final concentration was determined by absorbance at 259 nm using an extinction coefficient of 15 400 M -1 cm -1 . 11-12 A working solution of ATP (4 µM) was prepared immediately prior to use in 0.1 M Tris-HEPES (pH 7.5), 5 mM MgCl 2 , and 0.1% fat-free bovine serum albumin. A lyophilized powder containing luciferin (0.2 mg, M w 280) and luciferase (22 000 units) was freshly dissolved in 1.25 mL PBS, protected from light, and placed on ice. The final concentration of luciferin (570 µM) was determined by absorbance at 327 nm using an extinction coefficient of 18 000 M -1 cm -1 . 12 NaCN solution was freshly prepared at 1.0 M and brought to pH 7.5 with 6N HCl. The zVAD-fmk solution was made by dissolving 1.0 mg in 1.0 mL DMSO (final concentration, 2.14 mM) and stored at -20°C . Cells. The measurements were made on Jurkat and HL-60 cells. The cells were maintained in suspension cultures as described. 10 The cell count and viability were determined by light microscopy using a hemocytometer under standard trypan blue staining conditions. Incubation with Drugs. A fresh solution of RPMI-1640 medium (containing 6 mM Na 2 HPO 4 and 10 mM glucose), 10% fetal bovine serum, 2 µM Pd phosphor and 1% fat-free serum bovine albumin was stirred vigorously at 37°C for 30 min. Cells (usually 0.5 × 10 6 cells/mL) were suspended in this solution and incubated at 37°C with gentle stirring. The drugs (dactinomycin, doxorubicin, zVAD-fmk, and/or NaCN) were then added. For each condition, 1 mL of the cell suspension was placed in a 1 mL glass vial (8 mm clear Cellular ATP Content. Cellular ATP content was measured using the luciferin-luciferase bioluminescence system. 11-12 . Cellular acid extracts were prepared by adding 200 µL of 10% perchloric acid to each pellet of 0.5 × 10 6 cells. After sonication of the mixture on ice for 30 s, we collected the supernatant by centrifugation and neutralized it by adding 200 µL of 2 M KOH. The sample was incubated on ice for 15 min, and the precipitated KClO 4 was removed by centrifugation. The ATP content of the resulting supernatant was determined from the decay of luciferin bioluminescence.
Luminescence was measured at 37°C using a luminometer (Chrono-Log Corporation, Havertown, PA) connected to the Chrono-log AGGRO/LINK interface. The data were exported into Microsoft Excel and analyzed as described below. The reaction mixture contained, in a final volume of 0.4 mL, 0.1 M Tris-HEPES (pH 7.6), 5 mM MgCl 2 , 0.1% fat-free bovine serum albumin, and ATP (40-120 pmol) or cell acid extract (10 µL). The reaction was started by rapidly injecting 10 µL of luciferin/luciferase mixture (5 nmol luciferin and 176 units luciferase) from a 50 µL Hamilton syringe into 0.4 mL of rapidly stirred assay mixture.
The luminometer was calibrated as follows: For known concentrations of ATP between 0 and 0.2 µM, plots of luminescence intensity I versus t were obtained, intensity being measured every 0.5 s out to 300-600 s. The plots were well fit to the three-parameter function, I ) a + be -ct . Figure 1 
Results
Dactinomycin Decreases Cellular Respiration. , r 2 ) 0.994). The rate of respiration, k, the negative of the slope, was thus constant. For cells treated with 3 and 5 µM of drug (triangles and squares, respectively), the slopes (dashed and heavy lines, respectively) were -2.68 µM O 2 min -1 (r 2 ) 0.988) and -2.83 µM O 2 min -1 (r 2 ) 0.996), respectively. With 10 µM drug (X's in gray squares), the slope gradually became less negative with time; the best exponential fit is shown in Figure  2a . We also found the best linear fits to the first 13 data points (t < 70 min) and the last 17 data points (t > 70 min). The slope of the first was -3.18 µM O 2 min -1 (r 2 ) 0.978), the same as that for untreated cells, and the slope of the second was -2.10 µM O 2 min -1 (r 2 ) 0.997), ∼1/3 lower. , a 94% decrease from the value for untreated cells. The fact that the slopes were the same for 20 and 40 µM suggested that a limiting value had been reached.
The inhibition of cellular respiration by dactinomycin is not a direct effect on the mitochondria but is mediated by caspase activation. This is shown by the fact that it was completely blocked when 20 µM zVAD-fmk was present in the incubation mixture (Figure 2c ). In these experiments, 0.5 × 10 6 Jurkat cells/mL were used. For untreated cells (circles), the best-fit line (r 2 ) 0.985) had a slope of -1.157 µM O 2 min , essentially the same as that for untreated cells. Thus, because addition of the caspase inhibitor blocked the effect, it is clear that caspase activities were responsible for the inhibition of respiration.
The inhibitory effect of NaCN is shown in Figure 2d . In these experiments, 0.5 × 10 6 Jurkat cells/mL were used. The µM O 2 min -1 (significantly lower than that for untreated Jurkat cells). For the cells treated with 3 µM dactinomycin, the positive curvature in the [O 2 ] versus t curve showed that the respiration rate decreased with t for HL-60, as for Jurkat cells. However, the effect was evident at a much lower concentration (3 vs 10 µM), indicating a greater sensitivity to dactinomycin for the HL-60 cells.
HL 6 cells/mL media with 10% fetal bovine serum and 1% albumin and incubated at 37°C for up to 5 h, open to air. Three conditions were used: no additions, with 20 µM dactinomycin (which strongly inhibited respiration), and with 20 µM dactinomycin plus 50 µM zVAD-fmk (a combination that was without effect on respiration). At 1 h intervals after addition of dactinomycin, 1.0 mL samples of each cell suspension were taken for ATP analysis. As shown in Figure 4a , for untreated cells (diamonds), the cellular ATP level remained constant with t, consistent with the constant rate of respiration discussed above. The linear fit to the ATP levels exhibited a slope of zero within statistical error (-0.15 ( 0.22 nmol ATP min (grey squares) produced a rapid decrease in ATP level (by 46% after 1 h), which was followed by recovery to a level slightly below that for untreated cells by 4 h. The rapid decrease in ATP level for cells treated with dactinomycin + zVAD-fmk could not be due to a decrease in respiration rate because (i) the ATP level subsequently recovered almost to the level for untreated cells, (ii) no decrease in respiration was observed for cells incubated with dactinomycin + zVAD-fmk, and (iii) ATP levels did not decrease after 1 h when cells were treated with dactinomycin alone. The results of Figure 4b show that the decline in ATP level was associated with DMSO, which was introduced with the zVAD-fmk. We measured ATP content in 0.5 × 10 6 Jurkat cells under the following three conditions: addition of DMSO (23 µL) only (squares), addition of DMSO (23 µL) plus 10 µM dactinomycin (circles), and addition of zVAD-fmk (in 23 µL DMSO) plus 10 µM dactinomycin (triangles). A marked decrease in ATP level is shown during the first hour after addition for all three conditions. All three conditions showed a subsequent recovery of ATP, which was more noticeable in the absence of dactinomycin. Thus, it is likely that DMSO produced a transient cellular ATP leakage.
Addition of 10 mM NaCN to the cell suspension resulted in a greater than 90% decrease in cellular ATP level at 1 h. The level of ATP remained unmeasurable out to 5 h, thus establishing that the process of ATP synthesis occurred primarily in the respiratory chain.
Combination of Dactinomycin and Doxorubicin. When cells were treated with dactinomycin, the rate of respiration decreased gradually, starting at the time of drug addition (Figures 2-3) . In contrast, respiration in the presence of doxorubicin remained unchanged until about 150 min; it then decreased to a lower constant value. 10 In Figure 5 , r 2 ) 0.998, a 28% decrease). The filled squares in Figure 5a are for condition 4, exposure to 10 µM dactinomycin. The plot curvature was slight due to the lack of measurements at t < 50 min; the linear fit had a slope of -0.610 µM O 2 min -1 (r 2 ) 0.996). The lowering of k by 10 µM dactinomycin was 37%, larger than the lowering by 10 µM doxorubicin, showing that dactinomycin was more potent at reducing respiration. Figure 5b shows the oxygen consumption curves for conditions 2, 4, 5, and 6, listed above. The 10 µM doxorubicin condition (open squares) was discussed above. The 10 and 20 µM dactinomycin results (filled squares and , representing a 15% decrease in respiration.
For conditions 3-6, the plots of [O 2 ] versus t showed gradual curvature (an exponential fit to the results for 20 µM dactinomycin is shown in Figure 6 ). To compare respiration rates, we fitted the points for t > 175 min to lines. For conditions 3-6, the slopes were -0.491
-1 (r 2 ) 0.996), and -0.417 µM O 2 min -1 (r 2 ) 0.986), respectively. All represented a much greater decrease in respiration relative to no drug (55%, 66%, 51%, and 62%, respectively) than that obtained from doxorubicin alone. The decrease in respiration was about the same in all four cases. Thus, increasing the fraction of dactinomycin in the mixture, with a total drug concentration of 20 µM, had little effect. However, in the presence of dactinomycin the oxygenconsumption plot seems to have the gradual curve characteristic of dactinomycin and not the broken-line pattern characteristic of doxorubicin.
Similar results are obtained for HL-60 cells treated with dactinomycin and/or doxorubicin, as shown in Figure 7 . In , showing that this concentration of doxorubicin has little effect, reducing the respiration rate by less than 15%. The effect of 10 µM dactinomycin (filled squares) is much more pronounced: the best-fit line (r 2 ) 0.993) has a slope of -0.587 µM O 2 min -1 , corresponding to a reduction in respiration by 1 / 3 . The triangles are for cells exposed to 20 µM doxorubicin. As expected, the [O 2 ]-versus-t curve is well fit by two lines (see Figure 7a) . The line for t < 150 min has a slope of (-1.08 ( 0.13) µM O 2 min Theoretically, k should be the same for all samples at t ) 0, before the effect of drug is felt. In reality, errors in sampling will lead to different values of k at t ) 0. We correct for these errors by multiplying each calculated k by a constant to bring it into coincidence with k for untreated cells at t ) 0. This procedure yields the plots in Figure 8 . Note that the use of quadratic fitting functions makes the plots only a rough approximation of k. Figure 8a shows the k values obtained from the oxygen plots of Figure 2a articles Tao et al. mycin] ; discrepancies existed because of the approximations made in obtaining the k-versus-t curves. The near-coincidence of the 20 and 40 µM curves suggests that saturation occurs. The t at which k becomes zero, roughly 220 min for 20 or 40 µM, is the t at which respiration for these cells is completely halted by continuous exposure to the drug. Figure 8b shows the k values obtained from the oxygen plots of Figure 6 , which correspond to continuous exposure to dactinomycin-doxorubicin mixtures with 20 µM total drug. The horizontal line (constant k) is for cells not treated with drug. The next lines (for more rapidly decreasing k) are for 20 µM doxorubicin, 20 µM dactinomycin, 15 µM dactinomycin + 5 µM doxorubicin, 5 µM dactinomycin + 15 µM doxorubicin, and 10 µM dactinomycin + 10 µM doxorubicin. It is clear that 20 µM doxorubicin inhibits respiration much less than 20 µM dactinomycin or any of the drug mixtures. However, 20 µM dactinomycin is no more effective at inhibiting respiration than 10:10 or 5:15 drug mixtures. Thus, the effects of the drugs are not additive; it seems that a small admixture of dactinomycin increases the ability of doxorubicin to inhibit respiration. Indeed, the fact that the k values for the drug mixtures are below k for 20 µM dactinomycin suggests that the drugs act synergistically, the presence of doxorubicin augmenting the respirationinhibiting power of dactinomycin.
As mentioned previously, the effect of doxorubicin on mitochondrial respiration seems to be abrupt: the respiration rate remains unchanged for about 2 h, after which it decreases markedly and remains constant thereafter. We have fitted the [O 2 ]-versus-t curve for 20 µM doxorubicin to two straight lines, taking the intersection of the lines as one of the variable parameters. The resulting k value, which is equal to 1.883 for t < 121 min and 0.920 for t > 121 min, is shown in Figure 8b as a broken line.
Discussion
We report here measured cellular mitochondrial oxygen consumption (Figures 2 and 3 ) and ATP content (Figure 4 ) during continuous exposure to dactinomycin. We show that the drug inhibits respiration and lowers ATP content in Jurkat and HL-60 cells. The effect of dactinomycin on respiration is greater than that of doxorubicin at the same concentration. For both drugs, the inhibition of respiration is greater for higher drug concentrations. As a result, profound cellular ATP depletion occurs within 3-4 h of drug exposure. The presence of cyanide in these experiments inhibits respiration (Figure 2d ) and ATP content (see Results), establishing that both processesoccurred primarily in the mitochondrial respiratory chain. Although we view the decrease in ATP levels in the presence of dactinomycin as a consequence of the inhibition of respiration by the drug, it is possible that there is a direct effect of the drug on the enzymes catalyzing ATP formation or hydrolysis, or other components of mitochondrial function.
We utilized the pancaspase family inhibitor zVAD-fmk 8 to investigate whether these apoptosis-associated proteases mediated the inhibitory effects of dactinomycin on respiration. Although zVAD-fmk in fact blocked the dactinomycininduced decrease in oxygen consumption (Figure 2c) , it also produced a decrease in ATP level within 1 h of addition (Figure 4a ). This decrease was shown to be an effect of DMSO, introduced along with the zVAD-fmk; cellular leakage of ATP may have been involved. The level of ATP subsequently recovered, showing that zVAD-fmk did prevent dactinomycin from decreasing cellular ATP. It is clear from these observations (Figures 2-4) that the dactinomycininduced inhibition of respiration and ATP formation require caspase activities. Thus, the results shown in Figures 2-4 clearly describe the onset and severity of mitochondrial dysfunction during dactinomycin-induced apoptosis. The data also suggest that oxidative phosphorylation remains intact during the formation of apoptosomes and prior to caspase activation. The precise mechanism of caspase-mediated impairment of cellular respiration (inhibition of mitochondrial oxygen consumption and accompanying ATP synthesis) remains unknown. In addition to directly inhibiting oxidative phosphorylation, these proteases may impair other critical processes in ATP synthesis and hydrolysis. However, despite the fact that doxorubicin is known to interfere with components of the mitochondrial respiratory chain, this direct effect of the drug appears to be less important than the caspasemediated insults.
For the same concentration, dactinomycin is a more potent inhibitor of respiration than doxorubicin. Furthermore, we show that cells treated with dactinomycin exhibit gradually decreasing respiration (Figure 2b ), unlike cells treated with doxorubicin, for which there is an abrupt decrease. 10 The different shapes of the plots of [O 2 ] versus t produced by the two drugs (Figures 5 and 6 ) suggest that each drug executes cell death (apoptosis or necrosis) and interferes with the respiratory chain in a different way. Dactinomycin may induce cell death (apoptosis or necrosis) in a part of the population after a short incubation time, and in more of the population with longer times, whereas doxorubicin has little or no effect until ∼100 min, at which time a substantial fraction of the cells die.
Experiments in which Jurkat cells were incubated with mixtures of the two drugs, with the same total concentration, were also of interest. When the two drugs were used together, their effects were not at all additive; each drug seemed to enhance the action of the other. The significance of this finding remains to be explored further. The oxygenconsumption curves in the presence of both drugs resemble those for dactinomycin alone. This is not surprising: dactinomycin exerts some effects at early times. Later, when the abrupt drop in k produced by doxorubicin 10 should occur, k is so small that it would be difficult to detect the change in slope.
Observations relevant to the role of mitochondrial ∆ψ were presented in a series of reports by Green and coworkers, 6,7,9,15-16 who examined the apoptotic response of HL-60 and other cells following short exposures to dactinomycin, etoposide, or staurosporine. Apoptosis was initiated without noticeable changes in ∆ψ, which occurred only later in the cell-death process. 15 Studies of single cells treated with etoposide or dactinomycin showed that, if caspases were not activated, the mitochondria maintained generation of ATP even after the release of cytochrome c . 16 In contrast, caspase activation disrupted complexes I and II of the mitochondrial electron transport chain, resulting in diminished ∆ψ and generation of reactive oxygen species. 6 The results in Figures 2-4 agree with these reports and show that caspase activation impairs oxidative phosphorylation. The observed decrease in cellular ATP (Figure 4 ) emphasizes the importance of the mitochondrial cell-death pathway during apoptosis; 5 that is, the energy-converting processes shut down in cells exposed to high concentrations of toxins.
In isolated mouse liver mitochondria, oxygen uptake in response to substrates for complex I or II of the respiratory chain was inhibited in the presence of exogenous cytochrome c, tBid, and caspase-3. In contrast, oxygen uptake in response to substrates for complex IV remained intact. Somewhat similar results were observed in Jurkat cells treated with etoposide or staurosporine. 6 Moreover, in permeabilized HeLa cells, loss of ∆ψ and generation of reactive oxygen species were observed in the presence of caspase-3 and substrates for complex I or II, but not for those of complex IV. 6 In HeLa cells treated with 1.0 µM dactinomycin, loss of ∆ψ was observed at about 2 h and recovery about 30-60 min later. In Jurkat cells, incubation with 0.5 mM dactinomycin produced more than 60% apoptosis by 8 h.
In summary, the results presented here show that cells exposed to dactinomycin exhibit dose-dependent impairment of oxidative phosphorylation, which result from caspase activation.
